See the slide from our presentation from the BIO International Convention on "The State of Emerging Biotech Companies: Investment, Deal, and Pipeline Trends"
New research released by Vital Transformation (VT) shows that the Inflation Reduction Act (IRA) will stifle the ability of companies to continue research and development across a broad range of therapeutic areas.
BIO’s Industry Analysis Team presents FDA Approval Trends that are filterable by various attributes including: size of company, molecule size, disease area, and various expedited approval pathways.
This report investigates recent investment into antibacterial innovation and the current clinical pipeline that will help bridge the gaps in the antibacterial armamentarium.
